Menlo Park, California, United States
I am a senior finance executive with over 20 years of experience spanning all finance and related functions. I have successfully executed numerous equity, debt and other financing arrangements and have a proven ability to implement systems and controls to increase operating efficiency and ensure prompt, informative and reliable reporting. I enjoy building and leading high performance teams and working with department heads across the organization in order to develop prudent and meaningful operating plans. At the executive staff level I participate in strategic discussions and provide analysis that is critical in decision-making. My specific experience includes: IPO, Follow-on, RD, CMPO, ATM and private equity offerings; debt and royalty financings; investor relations and roadshows; partnering and M&A activities, including valuation analysis in multiple scenarios; budgeting, cost control and long-range forecasting; corporate cash and risk management; international tax planning; contract review and negotiation; management of internal and external reporting and SEC filings; implementation of internal control systems; ERP system selection, implementation and development; oversight of collaborations and international subsidiaries; management of outside counsel, external auditors, domestic and international tax experts and Sarbanes-Oxley consultants.
Headed finance function at this private biotechnology company seeking to address serious viral and liver diseases, prior to its acquisition by Mirum Pharmaceuticals, Inc. in January 2026. Responsible for all financial activities and member of Executive Team. • Supported negotiation and execution of merger agreement resulting in total consideration of up to $820M • Extensive involvement in presentations to potential acquirers, due diligence and transition planning • Prior to merger, spearheaded IPO readiness activities, including two confidential S-1 filings in early 2025 • Built company’s first integrated 3-year financial model to support Board decision-making
Led finance function at this private medical device company seeking to address the unmet needs of heart failure patients. Responsible for all financial functions, including fund-raising strategy and finance operations; also managed investor relations, corporate legal, human resources, information technology and facilities. • Developed 10-year financial model for valuation and organizational planning purposes • Coordinated investor meetings and conferences; presented corporate deck to analysts and bankers • Presented budget and analyses to Board; developed and gained approval for various resolutions
Nasdaq: ATRA. Manage finance operations at this public biotech company. Responsible for SEC filings, financial reporting, internal controls and SOX compliance, procurement and strategic sourcing, treasury, tax, insurance and other finance functions. Managed agendas, content and annual work plan for our Audit Committee and led meetings from the company side. • Partnered with BD in negotiation and sale of T-cell manufacturing facility to Fujifilm for $100M • Quarterbacked five follow-on offerings totaling over $800M and ATM facilities totaling $275M • Supported negotiation and execution of license and strategic collaboration agreement with Bayer • Participate in banker, investor and analyst meetings, non-deal roadshows and weekly IR meetings • Managed evolution of Finance function as company grew from 50 employees to over 500 worldwide • Implemented ERP system and supported distributor negotiations for commercial launch readiness • Took over procurement and strategic sourcing function; supported negotiations with CMOs/CROs
Nasdaq: SNSS. Managed finance operations at this public biotech company. Responsible for SEC filings, earnings releases, financial reporting, budgeting, analysis and long-term planning, internal controls and SOX compliance, treasury, domestic and international tax, risk management, insurance and other finance functions. Managed Audit Committee meetings and presented quarterly financial reports, analyses and discussion topics to Board. Participated heavily in commercial launch preparation and oversight of primary clinical research organization. • Completed equity offerings totaling $100M and at-the-market equity facility sales totaling $100M • Raised $25M in venture debt financing; executed pre-commercial royalty stream sale for $25M • Led international tax planning strategy, including Bermuda entity setup; prepared s.382 NOL analysis